Armed With an Ex-GlaxoSmithKline Alzheimer's Drug, Axovant Sciences Eyes $251 Million IPO

Published: Jun 02, 2015

Axovant Sciences, a newly-formed biotech developing a late-stage Alzheimer's therapy acquired from GSK, announced terms for its IPO on Monday.

The Hamilton, Bermuda-based company plans to raise $251 million by offering 17.9 million shares at a price range of $13 to $15. At the midpoint of the proposed range, Axovant Sciences would command a fully diluted market value of $1.36 billion and an enterprise value of $1.13 billion.

Help employers find you! Check out all the jobs and post your resume.

Back to news